KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Debt Ratio: 2019-2025

Historic Debt Ratio for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to 0.46.

  • Royalty Pharma's Debt Ratio rose 9.66% to 0.46 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.46, marking a year-over-year increase of 9.66%. This contributed to the annual value of 0.42 for FY2024, which is 11.54% up from last year.
  • As of Q3 2025, Royalty Pharma's Debt Ratio stood at 0.46, which was up 5.87% from 0.44 recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's Debt Ratio peaked at 0.46 during Q3 2025, and registered a low of 0.36 during Q2 2021.
  • In the last 3 years, Royalty Pharma's Debt Ratio had a median value of 0.42 in 2024 and averaged 0.42.
  • As far as peak fluctuations go, Royalty Pharma's Debt Ratio dropped by 11.51% in 2023, and later rose by 13.67% in 2025.
  • Quarterly analysis of 5 years shows Royalty Pharma's Debt Ratio stood at 0.41 in 2021, then climbed by 2.91% to 0.42 in 2022, then decreased by 11.51% to 0.37 in 2023, then grew by 11.54% to 0.42 in 2024, then increased by 9.66% to 0.46 in 2025.
  • Its Debt Ratio stands at 0.46 for Q3 2025, versus 0.44 for Q2 2025 and 0.43 for Q1 2025.